Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2011
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
Epistemonikos ID: d1f29f0f75c989b42a16dd07fac8d09619064e97
First added on: Mar 31, 2022